Yakuji Nippo

The wall of AG for biosimilars- Inhibiting the spread pointed out one after another Biosimilar Forum

With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

The wall of AG for biosimilars- "Inhibiting the spread" pointed out one after another Biosimilar Forum
October 16th, 2020

The spread of biosimilars has become a significant issue as the next target after achieving a generic product usage rate of 80%. At the "Biosimilar Forum" held on the web by the Biosimilar Council on the 14th, symposiasts pointed out that the authorized generic (AG) of biosimilars that appeared last year hindered the spread of biosimilars. However, opinions were calling for a review of medical fees, including introducing incentives to promote use.

(Continue to the next)

For this translated article in English, CM Plus Corporation shall have the copyright. Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.

A Series of Articles

About the Author

Related Articles

No information is found.

Digital Health
U.S. eHealth Journal

Vol. 73 (Issued at 2022/09/27)

日本で医療用医薬品ネット販売を検討中と一部報道で囁かれているAmazonだが、米国ではプライマリケアプログラム「Amazon Care」向けの買収や提携を積極的に強化し、ポストコロナのハイブリッド型ケアの将来を模索している。また、公的保険制度のメディケアでは、保険償還の対象となった遠隔患者モニタリング(RPM)の利用拡大傾向が調査で明らかとなった。スタートアップ各社では、レイオフのニュースが相次いだ一方、第2四半期の決算発表を通じて、各社の次の展開が少しずつ見えてきた。

Most Popular


The First Part: Promoting Social Implementation of Genome Medicine with Information Technology, Xcoo

Dr. Shinpaku


LSMIP Editorial Office


The second part: “MyChart” One App for All Personal Health Records

Sakura Ishikawa M.D.


MSA Partners, LLC


The Second Part: iCARE, Creating the Health of Workers Around the World

Dr. Shinpaku

Press Room